Regenerative Medical Technology Group, operating through Global Stem Cells Group, is a regenerative medicine company that trains physicians and sells them biologics and medical supplies. The company provides stem cell therapies, exosomes, and peptides to medical providers who treat chronic and aging-related conditions. The business model centers on a physician lifecycle where RMTG recruits providers through its education arm, the International Society for Stem Cell Applications (ISSCA). Once trained on standardized protocols, these physicians purchase recurring supplies of biologics from RMTG’s manufacturing division, Cellgenic. Cellgenic produces mesenchymal stem cells and therapy kits, acting as a high-margin revenue driver. RMTG also operates clinical facilities, such as the Cellular Institute in Mexico, which deliver patient care and function as hubs for protocol validation. A digital segment provides clinical decision support through an AI platform and mobile app. RMTG’s strategy utilizes this integrated ecosystem to drive product adoption and create switching costs for its customer base. The company pursues a land-and-expand growth model across Latin America, the Middle East, and Asia, entering markets via training events to establish physician networks before introducing its biologics and clinical partnerships.